Pure Global
NCT06214052

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

A Phase 2a, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
ViiV Healthcare·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
HIV Infections
Drug/Device/Intervention
VH4524184
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
ViiV Healthcare
Location
Bakersfield,Los Angeles,Los Angeles,Palm Springs,DeLand,Orlando,Tampa,Newark,Ciudad Autónoma de Buenos Aires,Almagro,Buenos Aires,Toronto,Montreal,Québec,Padova,Milano,Monza,San Pedro Garza García,Chi, Argentina,Canada,Italy,Mexico,Spain,United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Feb 14, 2024
End date
Sep 16, 2024
Enrollment
28 participants
Primary outcome

Maximum Change from Baseline in logarithm in 10 base (log10) Plasma HIV-1 Ribonucleic Acid (RNA) Through Day 10

Summary

The purpose of this study is to evaluate the safety, tolerability, ability of VH4524184 when
 given alone to reduce the amount of HIV (viral load) in people with HIV-1 infection who have
 never received antiretroviral therapy (treatment-naïve). Data from this study will be used to
 decide how VH4524184 can be best included in a full-treatment regimen for HIV-1 in the
 future.

ICD-10 classifications
HIV disease resulting in other viral infectionsHIV disease resulting in other bacterial infectionsHIV disease resulting in multiple infectionsAcute HIV infection syndromeHIV disease resulting in other infectious and parasitic diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06214052
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06214052 through Pure Global AI's free database. This Phase 2 trial is sponsored by ViiV Healthcare and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.